

## **Zydus receives final approval from the USFDA for Desmopressin Nasal Spray Solution USP**

---

*Ahmedabad, 04 October 2017*

Zydus Cadila has received the final approval from the USFDA to market Desmopressin Nasal Spray Solution USP, 10 mcg/0.1 mL per Spray, 5 mL bottle. It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.

Desmopressin Nasal Spray is indicated as an antidiuretic replacement therapy in the management of central diabetes insipidus, polyuria (excessive urination) and polydipsia (drinking excessive amounts of fluids) following head trauma or surgery in the pituitary region and nocturia (excessive urination at night).

The group now has more than 160 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

\*\*\*